Stock data
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP) reported net income of -US$28.35M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$12.42M | -US$28.35M | — |
| 2024 | — | — | -US$14.36M | -US$13.16M | — |
| 2023 | — | — | -US$13.58M | -US$7.60M | — |
| 2022 | — | — | -US$21.26M | -US$20.88M | — |
| 2021 | — | — | -US$57.52M | -US$58.01M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$4.52M | — |
| 2026-03-31 | — | -US$2.83M | — |
| 2025-12-31 | — | US$5.71M | — |
| 2025-09-30 | — | -US$3.11M | — |
| 2025-06-30 | — | -US$30.17M | — |
| 2025-03-31 | — | -US$0.78M | — |
| 2024-12-31 | — | -US$3.77M | — |
| 2024-09-30 | — | -US$3.41M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.